


„**Brief statement:** Even under application of an extremely high bioburden (Staph. aureus 380.000.000 KbE/mL; E.coli 440.000.000 KbE/mL) the sterility of the BTBS back sheet has been maintained over > 60 minutes.“ [...] „According to this the BTBS works as a sterile barrier.“



„**Brief statement:** The resorption is almost in the relation 1:1.“

„**Brief statement:** The product contains no bacterially available substrate. Over an exposure time of 4 days no increase of bioburden has been observed but rather a decrease.“

Interpretation:

- ① No germs can intrude through the BTBS into the wound dressing.
- ② Germs – generally being held responsible for the odour – are bonded.
- ③ What has been bound into the curea P1 has no chance to proliferate but will starve.

* Source: expert report from „Universitätsmedizin Göttingen“ (University Medical Centre Göttingen), Department of Medical Microbiology, Accredited Analytical Laboratory and Consultation Center, Humboldtallee 34A, DE 37073 Göttingen, Germany | Dr. med. U. Schmelz: Microbiological Validation of „curea P1“ from March 1st, 2011 or of „curea P2“ from May 25th, 2011.

** Source: expert report from „Universitätsmedizin Göttingen“ (University Medical Centre Göttingen), Department of Medical Microbiology, Accredited Analytical Laboratory and Consultation Center, Humboldtallee 34A, DE 37073 Göttingen, Germany | Dr. med. U. Schmelz: Determination of the resorptive potential of the wound dressings „curea P1“ and „curea P2“ with respect to whole blood, plasma, serum and physiological saline from 30th March, 2012.

We will gladly send you copies of the complete expertise if you like. Just give us a notification:
info@curea-medical.de or +49 36071 9009500.

SuperCore®: Patent held by the parent company of curea medical GmbH, McAirLaid's Vliesstoffe GmbH

pictures: © Alexander Rath/fotolia; © curea medical GmbH